Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Accounts Payables (2022 - 2025)

Historic Accounts Payables for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $2.6 million.

  • Century Therapeutics' Accounts Payables rose 73.13% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 73.13%. This contributed to the annual value of $3.1 million for FY2024, which is 1218.53% up from last year.
  • Latest data reveals that Century Therapeutics reported Accounts Payables of $2.6 million as of Q3 2025, which was up 73.13% from $3.2 million recorded in Q2 2025.
  • Over the past 5 years, Century Therapeutics' Accounts Payables peaked at $9.9 million during Q1 2022, and registered a low of $2.6 million during Q3 2024.
  • Its 4-year average for Accounts Payables is $4.2 million, with a median of $3.5 million in 2023.
  • As far as peak fluctuations go, Century Therapeutics' Accounts Payables plummeted by 6487.42% in 2023, and later skyrocketed by 1218.53% in 2024.
  • Quarter analysis of 4 years shows Century Therapeutics' Accounts Payables stood at $5.5 million in 2022, then plummeted by 49.74% to $2.7 million in 2023, then grew by 12.19% to $3.1 million in 2024, then decreased by 14.89% to $2.6 million in 2025.
  • Its Accounts Payables stands at $2.6 million for Q3 2025, versus $3.2 million for Q2 2025 and $3.6 million for Q1 2025.